CELLforCURE (SEQENS)
Les Ulis, FR
Program data pending ClinicalTrials.gov matching
· Last scored 2026-04-02
80.3
Signal Score
○ FDA Inspections
○ Clinical Trials
○ SEC Filings
○ Press
✓ EMA GMP (4)
○ MHRA GMP
Quick Facts: CELLforCURE (SEQENS)
- Signal Score
- 80.3/100 (as of 2026-04-02)
- Quality Compliance
- 100.0/100 — No FDA inspection records found for this manufacturer
- Headquarters
- Les Ulis, FR
- Modalities
- CAR-T, Cell Therapy
- Active Programs
- No ClinicalTrials.gov matches confirmed
- Data Sources
- FDA Data Dashboard, ClinicalTrials.gov, SEC EDGAR, press monitoring
- Scored By
- CDMO Signal — independent CDMO intelligence platform
Signal Score & Pillar Breakdown
Quality Compliance
100.0
No FDA inspection records found for this manufacturer
Quality score requires FDA inspection data
Source: FDA Data Dashboard
No FDA inspection records found for this manufacturer · Quality score requires FDA inspection data
FDA InspectionsNo US records on file
EMA GMP Certificates4 on record
No FDA inspection records found for this manufacturer
Quality score requires FDA inspection data
Operations
—
No ClinicalTrials.gov facility matches confirmed for this manufacturer.
Programs
— no verified data
Sponsors— no verified data
ModalitiesCAR-T, Cell Therapy
No clinical trial matches found for this manufacturer
Operational score requires ClinicalTrials.gov data
Data sourced from ClinicalTrials.gov, FDA, SEC EDGAR, and verified press only. No unverified estimates shown.
Financial Stability
68.0
Parent company: SEQENS
Financial assessment: 68.0/100
Source: SEC EDGAR, press monitoring
Profile-based financial assessment
SEC FilingsPrivate company
Parent company: SEQENS
Financial assessment: 68.0/100
Capacity
58.0
1 manufacturing site: Les Ulis, France
Modalities: CAR-T, Cell Therapy
Capacity assessment: 58.0/100
Sites: Les Ulis, France
Source: SEC EDGAR, press monitoring, company profiles
1 manufacturing site
1 manufacturing site: Les Ulis, France
Modalities: CAR-T, Cell Therapy
Capacity assessment: 58.0/100
EMA GMP Compliance 4 certificates
2022-06
2022-06
2022-06
2022-06
Compliant
Non-Compliant
| Certificate | Site | Country | Inspection Date | Status |
|---|---|---|---|---|
| 2022_HPF_FR_173_IV_P_2025 | Cellforcure | France | 2022-06-10 | COMPLIANT |
| 2022_HPF_FR_174_IV_P_2025 | Cellforcure | France | 2022-06-10 | COMPLIANT |
| 2022_HPF_FR_173_IV | Cellforcure | France | 2022-06-10 | COMPLIANT |
| 2022_HPF_FR_174_IV | Cellforcure | France | 2022-06-10 | COMPLIANT |
Source: EMA EudraGMDP · Retrieved Apr 05, 2026
Represent this organization? Contact us to verify or update this profile.
See all CDMOs in:
Similar CDMOs
Excellos
La Rochelle, FR
Signal Score: 59.0
Cell Therapy, CAR-T
Charles River Laboratories
Newbury Park, CA · Memphis, TN · Keele, UK · Rockville, MD
Signal Score: 92.2
CAR-T, Cell Therapy, Gene Editing, Plasmid, AAV, Lentiviral
Bristol Myers Squibb (CGT Mfg)
Bothell, WA · Warren, NJ
Signal Score: 90.7
CAR-T, Cell Therapy
City of Hope (T Cell Manufacturing)
Duarte, CA
Signal Score: 84.9
CAR-T, Cell Therapy
Minaris Advanced Therapies
Philadelphia, PA · Allendale, NJ · Munich, DE · Yokohama, JP
Signal Score: 83.5
CAR-T, Cell Therapy